MYLAN's MAXZIDE IS "APPROVABLE" AT FDA: LEDERLE TO MARKET BRAND COMPETITION TO SMITHKLINE's No. 3-RANKED DYAZIDE; FINAL APPROVAL ANTICIPATED "IMMINENTLY"
• By The Pink Sheet
Mylan's full NDA application for a triamterene/hydrochlorothiazide combo, Maxzide, reached the "approvable" stage at FDA on Sept. 28. Final FDA clearance is pending resolution of labeling issues. Mylan reportedly has responded to all follow-up questions in FDA's approvable letter to the firm. The generic mfr. expects clearance "imminently." Lederle will market the drug, which is the first combination product to contain the same ingredients as SK&F's Dyazide. Maxzide contains 50 mg hydrochlorothiazide and 75 mg triamterene, an increased dosage over Dyazide's 25 mg hydrochlorothiazide and 50 mg triamterene. The Maxzide clearance will set up an interesting brand-to-brand competition in the triamterene potassium sparing/diuretic combo market. SK&F has built Dyazide, a drug first approved in the U.S. over 20 years ago, into the third largest retail drug by sales volume. In 1983, SK&F did $210 mil. In sales of Dyazide to retail pharmacies, according to Pharmaceutical Data Services. Because of the dosage differences, Maxzide is not technically a generic equivalent for Dyazide. Lederle will be entering the potassium-sparing market with the same active ingredients as Dyazide. However, the product will have to be sold as a brand competitor. Trade sources expect Maxzide to carry a once-a-day indication. Dyazide is currently indicated for "one or two capsules twice daily after meals." Labeling notes though that "some patients may be maintained on one capsule daily or every other day." More than 70% of Dyazide use is reportedly in the once-daily dosing. Lederle has been gearing up for the Maxzide launch. In an interim statement on third quarter results issued Oct. 16, Lederle's parent, American Cyanamid, attributed a decline in medical operating earnings to "substantial pre-launch expenditures for new products." Lederle specifically cited Maxzide and "the anticipated approval by the U.S. FDA." The company further predicted a strain on near-term earnings due to "aggressive spending" for new medical products. SK&F has been working on a new formulation for Dyazide which will improve bioavailability of the drug. The company plans to submit data to FDA to support a supplemental NDA for the new formulation. The company says the clinical studies to support the new formulation have been completed and the submission is awaiting final analysis of data. The supplemental filing is "some months" away.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
In line with new President Lee’s campaign pledges, South Korea's newly confirmed health minister is expected to tackle key issues including a prolonged doctors' conflict, essential drug supplies and R&D support for the industry.
The removal of CBER Director Prasad comes after a wave of right-wing backlash to his appointment over the past few days that was also critical of his decision to ask Sarepta to suspend all sales of the DMD gene therapy Elevidys. FDA reversed its decision the day before Parsad's departure.
Meanwhile, companies continue discussions with the Trump Administration over ways of increasing what European nations pay for drugs as an alternative to imposing a Most Favored Nation drug pricing policy in the US.